Covariate AD N (%) SCC N (%) p-values Sex 63/63 96/96 0.097 M

Slides:

Advertisements

Similar presentations

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

Advertisements

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

Figure S1 b a c Supplement Figure 1. Basic functional characterization of B10G5 antibody. a. B10G5 neutralizing free sMICA in in vitro assay. Various concentration.

Herceptin + 17-AAG Combination BT-474 Tumors

Supplementary Figures. Figure Legends Suppl. Figure 1. Flow cytometry analysis to monitor apoptosis levels in MCF-7 cells. As control MCF-7 cells grown.

Treatment with ipilimumab

TUMOR PD-L1 TIL PD-L1 TUMOR & TIL PD-L1 Age Low High P value R Pearson

Large cell undifferentiated carcinoma of lung

Volume 18, Issue 3, Pages (January 2017)

Volume 23, Issue 2, Pages (February 2013)

Serpin Peptidase Inhibitor Clade A Member 1 (SerpinA1) Is a Novel Biomarker for Progression of Cutaneous Squamous Cell Carcinoma Mehdi Farshchian, Atte.

Lung squamous cell carcinoma

Volume 67, Issue 6, Pages (June 2015)

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

Elevated FOXC2 Expression Promotes Invasion of HCC Cell Lines and is Associated with Poor Prognosis in Hepatocellular Carcinoma Cell Physiol Biochem 2017;44:99–109.

Supplementary Figure S2

Treatment with ipilimumab

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Staging Cancer.

Fig. S1 PIPKI is highly expressed in cancer cell lines

AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma Daniel L. Albertus, BS, Christopher.

Sarah A. Best, Amy N. Nwaobasi, Chrysalyne D. Schmults, Matthew R

MR1-TM inhibits the development of severe ATD and pSS in CD28−/− NOD

E-cadherin expression associated with differentiation and prognosis in patients with non–small cell lung cancer Dage Liu, MD, Cheng-long Huang, MD, Kotaro.

Ming Hong Shen, Paulina Samsel, Louise L

Supplementary Table 1 Akt2 is required for NNK-induced lung tumorigenesis but not for urethane-induced lung tumorigenesis while Akt3 may act as a tumor.

Sarah A. Best, Amy N. Nwaobasi, Chrysalyne D. Schmults, Matthew R

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Volume 67, Issue 6, Pages (June 2015)

Molecular Therapy - Nucleic Acids

Evelyn C. Nieves, Tomomi Toubai, Daniel C

Putative Stem Cell Markers in Non–Small-Cell Lung Cancer: A Clinicopathologic Characterization Willam Sterlacci, MD, Spasenija Savic, MD, Michael Fiegl,

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Fig. 8. In vivo suppression of MM by CMLD

Figure 2S (Supplementary Data)

Figure S2 Supplementary data a b CCA1 CCA2 CCA4 CCA3 CCA5 EGFR HER2

Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer David J. Stewart, MD, Maria I. Nunez, MD,

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Disease-specific survival

Preliminary Investigation of the Clinical Significance of Detecting Circulating Tumor Cells Enriched from Lung Cancer Patients Chi Wu, MD, Huaijie Hao,

Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with.

Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities Matthew P. Humphries, PhD, Stephen.

Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease Isao Tawara,

Volume 18, Issue 3, Pages (January 2017)

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.

Volume 19, Issue 1, Pages (April 2017)

Volume 13, Issue 4, Pages (April 2008)

Clinicopathologic Features and Computed Tomographic Findings of 52 Surgically Resected Adenosquamous Carcinomas of the Lung Yukio Watanabe, MD, Koji.

Ly6/uPAR-Related Protein C4

Supplementary Fig S1, Zembutsu H et al.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Volume 19, Issue 1, Pages (April 2017)

Supplementary Figure S1

This month in Gastroenterology

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

Supplementary figure 1 A B Water (Control) Pre-alcohol Post-alcohol

TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor tissues. TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor.

Patients’ characteristics

Histopathology of anal tissue.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

Deletion of Tgfbr2 in myeloid cells elevated IFN-γ production in CD8+ T cells, and systemic IFN-γ neutralization diminished metastasis inhibition in Tgfbr2MyeKO.

Supplemental Material

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

GCS-100 selectively kills KRAS-addicted lung tumors.

Repulsive Guidance Molecule-a Is Involved in Th17-Cell-Induced Neurodegeneration in Autoimmune Encephalomyelitis Shogo Tanabe, Toshihide Yamashita Cell.

H & E = hematoxylin and eosin.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Presentation transcript:

Covariate AD N (%) SCC N (%) p-values Sex 63/63 96/96 0.097 M 31 (49.2%) 60 (62.5%) F 32 (50.8%) 36 (37.5%) Smoking Status 48/63 84/96 0.232 Current 24 (50%) 51 (60.7%) Former 20 (41.6%) 29 (34.5%) Never 4 (8.3%) 4 (4.8%) Pathologic Stage 94/96 0.001 I 35 (55.5%) 24 (25.5%) II 23 (36.5%) 29 (31%) III & IV 5 (8%) 41 (43.6%) Degree of Differentiation 60/63 93/96 0.224 Poor 11 (18.3%) 22 (23.7%) Moderate 41 (68.3%) 64 (68.8%) Well 8 (13.3%) 7 (7.5%) Survival 50/63 85/96 0.286 Alive 43 (86%) 69 (81.2%) Dead 7 (14%) 16 (18.8%) Supplemental Table 1

A. B. H520 Rapa Flow Cytometry PD-L1 pS6S235/236 α-tubulin Veh 16h 24h H520 Rapa Flow Cytometry Supplementary Figure 1

16h Veh 2h 6h 24h pERKT202/Y204 pAKTS473 AKT ERK -tubulin PD-L1 CL30 IO33 CL25 U0126 A. B. H157 U0126 Supplementary Figure 2

Squamous Cell Carcinoma TMA Squamous Cell Carcinoma TMA Membrane PD-L1 Scoring Scale +1 +2 +3 C. pS6S235/236 Scoring Negative Positive B. Adenocarcinoma TMA Stain Lung Tissue Location +1 +2 +3 PD-L1 Tumor Membrane 42 (67.7%) 4 (6.5%) 6 (9.7%) 10 (16%) Normal 62 (100%) Squamous Cell Carcinoma TMA 46 (47.9%) 12 (12.5%) 14 (14.6%) 24 (25%) D. Adenocarcinoma TMA Stain Tissue Negative Positive pS6S235/236 Tumor 9 (14.5%) 53 (85.5%) Squamous Cell Carcinoma TMA 33 (34.4%) 63 (65.6%) Supplementary Figure 3

PD-L1 pS6S235/236 Overlay IHC Pseudocolor Supplementary Figure 4.

* n.s. C. A. B. N=6 4.5mg/kg LD; 1.5mg/kg vehicle QOD and 150μg IgG weekly i.p. IO33 cells sub-cut. Sacrifice 3wks tx Tumors 3-5mm 4.5mg/kg LD; 1.5mg/kg rapa QOD and 150μg αPD-1 weekly i.p. Rapa&αPD-1 Veh&IgG Cl. Caspase 3 Ki67 * pHP1-γ * D. E. F. CD8+ CD4+FoxP3+ CD4+ * n.s. Supplemental Figure 5

4.5mg/kg LD; 1.5mg/kg rapa QOD B. D. ** CD8+ CD4+FoxP3+ E. N=6 Tumors 3-5mm IO33 cells sub-cut. Sacrifice 3 weeks 4.5mg/kg LD; 1.5mg/kg rapa QOD Syngeneic A/J mice 150μg IgG weekly i.p. 150μg αPD-1 weekly i.p. 4.5mg/kg LD; 1.5mg/kg veh QOD Rapa&IgG Veh&αPD-1 Rapa&αPD-1 N=4 C. Supplementary Figure 6.